Literature DB >> 31806968

Improving The Oral Absorption Of Nintedanib By A Self-Microemulsion Drug Delivery System: Preparation And In Vitro/In Vivo Evaluation.

Hongfei Liu1, Jiaao Mei1, Ying Xu1, Lei Tang1, Daquan Chen2, Yating Zhu1, Shuguang Huang1, Thomas J Webster3, Hui Ding4.   

Abstract

OBJECTIVE: Nintedanib (NDNB) is a triple receptor tyrosine kinase inhibitor with poor solubility in neutral conditions and low bioavailability. A self-microemulsifying drug delivery system (SMEDDS) of NDNB was developed to improve drug solubility in physical conditions and absorption in vivo.
METHODS: The NDNB-SMEDDS formulation was optimized via pseudo-ternary phase diagrams. The physicochemical properties of NDNB-SMEDDS, viz., morphological observation, droplet size, stability, compatibility and in vitro release were investigated. The permeability of NDNB-SMEDDS was detected using both a Caco-2 cell monolayer in vitro and an intestinal perfusion study in vivo. Furthermore, the pharmacokinetic characteristics of NDNB-SMEDDS were evaluated.
RESULTS: The optimal formulation was composed of MCT as an oil phase, RH 40 as a surfactant and ethylene glycol as a co-surfactant. The average droplet size of the microemulsion was about 23 nm with good stability within 30 days. The formulation did not exhibit any obvious cytotoxic effect on Caco-2 cells. Permeability of nintedanib in a Caco-2 cell monolayer was enhanced by 2.8-fold upon incorporation in SMEDDS compared with the drug solution. The intestinal perfusion study demonstrated that the P app of NDNB-SMEDDS increased by 3.0-fold in the entire intestine and 3.2-fold in the colon in comparison with the drug solution. The pharmacokinetics study showed that the AUC of the NDNB-SMEDDS increased significantly.
CONCLUSION: This study showed that the self-microemulsion formulations could improve the absorption of nintedanib, and can thus serve as a promising carrier for the oral delivery of nintedanib.
© 2019 Liu et al.

Entities:  

Keywords:  Caco-2 cell; bioavailability; intestinal perfusion; nintedanib; permeability; pharmacokinetics; self-microemulsion drug delivery system; solubility

Mesh:

Substances:

Year:  2019        PMID: 31806968      PMCID: PMC6847991          DOI: 10.2147/IJN.S224044

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  33 in total

1.  Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp.

Authors:  Xiao-dan Wang; Min-xin Meng; Ling-bo Gao; Ting Liu; Qiang Xu; Su Zeng
Journal:  Int J Pharm       Date:  2009-05-22       Impact factor: 5.875

2.  Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.

Authors:  Yoshie Masaoka; Yusuke Tanaka; Makoto Kataoka; Shinji Sakuma; Shinji Yamashita
Journal:  Eur J Pharm Sci       Date:  2006-06-27       Impact factor: 4.384

3.  Dissolution evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery systems for pH-sensitive drug loratadine.

Authors:  Haiyan Li; Yonggang Tan; Lixia Yang; Lijun Gao; Tao Wang; Xi Yang; Dongqin Quan
Journal:  J Microencapsul       Date:  2014-11-21       Impact factor: 3.142

4.  Investigating drug absorption from the colon: Single-pass vs. Doluisio approaches to in-situ rat large-intestinal perfusion.

Authors:  Isabel Lozoya-Agullo; Moran Zur; Noa Fine-Shamir; Milica Markovic; Yael Cohen; Daniel Porat; Isabel González-Álvarez; Marta González-Álvarez; Matilde Merino-Sanjuán; Marival Bermejo; Arik Dahan
Journal:  Int J Pharm       Date:  2017-05-10       Impact factor: 5.875

Review 5.  Enzyme decorated drug carriers: Targeted swords to cleave and overcome the mucus barrier.

Authors:  Claudia Menzel; Andreas Bernkop-Schnürch
Journal:  Adv Drug Deliv Rev       Date:  2017-10-24       Impact factor: 15.470

Review 6.  What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

Authors:  Jaume Capdevila; Alfredo Carrato; Josep Tabernero; Enrique Grande
Journal:  Crit Rev Oncol Hematol       Date:  2014-05-14       Impact factor: 6.312

7.  Hypolipidemic potential of perillaldehyde-loaded self-nanoemulsifying delivery system in high-fat diet induced hyperlipidemic mice: Formulation, in vitro and in vivo evaluation.

Authors:  Emmanuel Omari-Siaw; Yuan Zhu; Houyong Wang; Wei Peng; Caleb Kesse Firempong; Yuan Wen Wang; Xia Cao; Wenwen Deng; Jiangnan Yu; Ximing Xu
Journal:  Eur J Pharm Sci       Date:  2016-02-03       Impact factor: 4.384

Review 8.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

9.  Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

Authors:  Frank Hilberg; Ulrike Tontsch-Grunt; Anke Baum; Anh T Le; Robert C Doebele; Simone Lieb; Davide Gianni; Tilman Voss; Pilar Garin-Chesa; Christian Haslinger; Norbert Kraut
Journal:  J Pharmacol Exp Ther       Date:  2017-12-20       Impact factor: 4.030

10.  Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity.

Authors:  Guru R Valicherla; Kandarp M Dave; Anees A Syed; Mohammed Riyazuddin; Anand P Gupta; Akhilesh Singh; Kalyan Mitra; Dipak Datta; Jiaur R Gayen
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

View more
  2 in total

1.  Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation.

Authors:  Ravinder Verma; Ajeet Kaushik; Rafa Almeer; Md Habibur Rahman; Mohamed M Abdel-Daim; Deepak Kaushik
Journal:  Int J Nanomedicine       Date:  2021-02-09

2.  Preparation and Study of Folate Modified Albumin Targeting Microspheres.

Authors:  Quanbin Zha; Ling Zhang; Yuhua Guo; Rui Bao; Feng Shi; Yongkang Shi
Journal:  J Oncol       Date:  2022-01-28       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.